Biotechnology Investors Cheer Acelyrin’s Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients – Acelyrin (NASDAQ:SLRN) Read more
Biotechnology Acelyrin’s Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study – Acelyrin (NASDAQ:SLRN) Read more
